Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
ConclusionsCompared to CT alone, ICIs were safer and are recommended for frail patients. Conversely, CT + ICIs or ICIs combinations increased infection risk. Further studies are required to identify high-risk patients and evaluate the need for CT dose reduction or prophylactic myeloid growth factors. (Source: Targeted Oncology)
Source: Targeted Oncology - July 5, 2021 Category: Cancer & Oncology Source Type: research
Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer
ConclusionEntinostat with exemestane showed reasonable safety, tolerability, and encouraging efficacy in Chinese patients with HR+/HER2 − MBC. These results support further evaluation in a randomized, double-blind Phase III study with a weekly 5 mg entinostat dose in a Chinese population.Trial RegistrationNCT02833155. (Source: Targeted Oncology)
Source: Targeted Oncology - July 1, 2021 Category: Cancer & Oncology Source Type: research
Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study
ConclusionsEarly treatment interruption, which exerted a negative effect for TKIs, was a preferable event for nivolumab plus ipilimumab when considering PFS. Furthermore, early administration of high-dose corticosteroids did not diminish the anti-tumor effect of nivolumab plus ipilimumab. (Source: Targeted Oncology)
Source: Targeted Oncology - June 26, 2021 Category: Cancer & Oncology Source Type: research
Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis
ConclusionsWe provide an estimate for the risks and benefits of participation in pediatric phase II cancer trials. These data may be used as an empirical basis for informed communication about benefits and burdens in pediatric oncology research. (Source: Targeted Oncology)
Source: Targeted Oncology - June 10, 2021 Category: Cancer & Oncology Source Type: research
Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy
ConclusionsOur results indicate the potential for the use of sBCMA as a new biomarker for monitoring patients with RRMM. (Source: Targeted Oncology)
Source: Targeted Oncology - June 7, 2021 Category: Cancer & Oncology Source Type: research
Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study
ConclusionsDespite the limitations of a retrospective analysis and the small number of patients, the benefit of adjuvant imatinib 400 mg daily in high-risk patients appeared relevant. Patients with advanced disease receiving imatinib 400 mg with subsequent dose escalation had a TIF similar to that observed with an initial dose of 800 mg. Intra-patient dose escalation in this setting might be an option. (Source: Targeted Oncology)
Source: Targeted Oncology - June 5, 2021 Category: Cancer & Oncology Source Type: research
The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy
ConclusionsPIV may guide the treatment decision process and the development of novel first-line treatment strategies in melanoma, but warrants further study and validation. (Source: Targeted Oncology)
Source: Targeted Oncology - June 2, 2021 Category: Cancer & Oncology Source Type: research
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort
ConclusionsBintrafusp alfa showed signs of clinical efficacy with a manageable safety profile in patients with heavily pretreated, advanced esophageal adenocarcinoma.Clinical Trials RegistrationNCT02517398. (Source: Targeted Oncology)
Source: Targeted Oncology - May 19, 2021 Category: Cancer & Oncology Source Type: research
Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review
ConclusionsICI neoadjuvant therapy may be a safe and efficacious treatment option in patients with resectable NSCLC. Combined with chemotherapy, ICI appears to be more efficacious, but displays more adverse events. More ongoing clinical trials will shed further light on the safety and efficacy of ICI neoadjuvant therapy in patients with resectable NSCLC. (Source: Targeted Oncology)
Source: Targeted Oncology - May 13, 2021 Category: Cancer & Oncology Source Type: research
Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study
ConclusionsIn post-marketing surveillance data, VEGFR-TKIs are associated with increased reporting of various CVAEs, including pericardial diseases, particularly non-malignant pericardial effusion, and aortic dissections. Moreover, VEGFR-TKIs differ in their CVAE reporting patterns. Clinicians should be conscious of these findings in the care of VEGFR-TKIs recipients.Graphic AbstractCardiovascular toxicities of VEGFR-TKIs in the FDA adverse events reporting system (FAERS) database. Post-marketing data of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI)-associated cardiovascular toxicities...
Source: Targeted Oncology - May 10, 2021 Category: Cancer & Oncology Source Type: research
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
ConclusionsIn our study, p53 overexpression was associated with anti-EGFR treatment resistance in patients withRAS/BRAF WT mCRC, as confirmed in a validation cohort. Larger studies are needed to validate the role of p53 and investigate EGFR cross-talk in these patients. (Source: Targeted Oncology)
Source: Targeted Oncology - May 10, 2021 Category: Cancer & Oncology Source Type: research
Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies
ConclusionsDSP-7888 Dosing Emulsion was well tolerated, with no dose-limiting toxicities, in patients with recurrent or advanced malignancies. Higher WT1-specific CTL induction activity was noted with ID compared with SC administration; because of this, the ID route was selected for further evaluation in the clinical program.Trial registrationClinicalTrials.gov identifier: NCT02498665. (Source: Targeted Oncology)
Source: Targeted Oncology - May 3, 2021 Category: Cancer & Oncology Source Type: research
Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C
ConclusionsThe MTD of savolitinib was 400 mg qd in both cohorts. Data demonstrate an acceptable safety profile for savolitinib alone, or with osimertinib.Trial registration: Clinicaltrials.gov; NCT02143466; 21 May 2014. (Source: Targeted Oncology)
Source: Targeted Oncology - May 3, 2021 Category: Cancer & Oncology Source Type: research
The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcS é-Crizotinib Program
ConclusionsLarge-scale screening forMET-amplified esogastric adenocarcinomas is feasible.MET amplification was observed in 5.5% of gastric and 12.8% of esophageal adenocarcinomas. Crizotinib shows encouraging results in selected patients. Thus, c-MET inhibition forMET-amplified tumors deserves further evaluation.Trial Registration NumberNCT02034981.Date of Registration14 January 2014. (Source: Targeted Oncology)
Source: Targeted Oncology - May 1, 2021 Category: Cancer & Oncology Source Type: research
TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting
ConclusionsAlthough the hazard ratio for overall survival suggested a higher risk of death for patients withNTRK gene fusions, the difference was not statistically significant. Co-occurrence ofNTRK gene fusions and other actionable biomarkers was uncommon. (Source: Targeted Oncology)
Source: Targeted Oncology - April 24, 2021 Category: Cancer & Oncology Source Type: research
